Latest filing published 10 Mar 2026 for Halozyme Therapeutics, INC., €1.1M.
Filing timeline
BuySaleInsider track record
Cortney Caudill: trading record in brief
Cortney Caudill discloses dealings in Halozyme Therapeutics, Inc. to SEC (Form 4). The record holds 9 filings, for trades running from 1 November 2025 to 10 March 2026.
No open-market purchase appears, only 4 sales worth €1.9M. Outside the open market, there are 1 share grant and 4 option exercises. So far in 2026, the count stands at no purchases and 3 sales.
The latest filing, published on 10 March 2026, reports an open-market sale of €1.1M in Halozyme Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Cortney Caudill
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 17,900 shares@ US$67.7540.1% of flowCommon StockSEC:0001159036-26-000033:1
- 2,100 shares@ US$68.254.7% of flowCommon StockSEC:0001159036-26-000033:2
- 1,546 shares@ US$33.511.7% of flowCommon StockSEC:0001159036-26-000033:3
- 8,857 shares@ US$67.6419.7% of flowCommon StockSEC:0001159036-26-000033:4
- 20,000 shares@ US$33.51100.0% of flowCommon StockSEC:0001159036-26-000033:0
- 1,037 shares@ US$70.982.4% of flowCommon StockSEC:0001159036-26-000031:1
- 2,666 shares0Common StockSEC:0001159036-26-000031:0
- 4,263 shares@ US$65.199.2% of flowCommon StockSEC:0001159036-25-000075:1
- 9,326 shares0Common StockSEC:0001159036-25-000075:0
9 of 9 declarations
